Rivernorth Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Rivernorth Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-58,548	Closed	-$1.76K	–	707
2023 Q1	$1.76K	Hold	58,548	–	–	﹤0.01%	599
2022 Q4	$2.93K	Buy	58,548 +25,216	+76%	+$898	﹤0.01%	634
2022 Q3	$1K	Hold	33,332	–	–	﹤0.01%	848
2022 Q2	$2K	Hold	33,332	–	–	﹤0.01%	792
2022 Q1	$6K	Hold	33,332	–	–	﹤0.01%	791
2021 Q4	$19K	Hold	33,332	–	–	﹤0.01%	663
2021 Q3	$27K	Hold	33,332	–	–	﹤0.01%	505
2021 Q2	$35K	Hold	33,332	–	–	﹤0.01%	457
2021 Q1	$42K	Buy	+33,332	New	+$54K	﹤0.01%	416

Rivernorth Capital Management's EUCRW Position: Q2 2023 in Review

Rivernorth Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 58,548 shares — an estimated $1.76K sold.

Rivernorth Capital Management first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $42K in Q1 2021. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Rivernorth Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Rivernorth Capital Management sold 58,548 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1.76K.
Rivernorth Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
Rivernorth Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $42K in Q1 2021.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Rivernorth Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.